Life of GENEO

GENEO Capital Entrepreneur supported GBNA Santé in the acquisition of three facilities from the Francheville Perigord Santé group, strengthening GBNA's position as a leading hospital group in the Nouvelle-Aquitaine region, with a total of 12 healthcare facilities. This acquisition, announced in June and formally completed in September, was partly financed by a capital increase in which GENEO Capital Entrepreneur, which has been supporting GBNA since 2021, participated along with UI Investissement.

ChapsVision, the data enhancement specialist, raises €90 million to accelerate its development on the European market through targeted acquisitions. This round of financing is led by Qualium Investissement with the participation of GENEO, and historical investors Tikehau Capital and Bpifrance, who have subscribed to this new round of funding.

Stéphanie Kordonian joins GENEO Capital Entrepreneur's team of investment professionals with extensive experience in the SME and ETI segment.
A graduate of ESSEC business school, Stéphanie is a corporate finance professional, specializing in SMEs.

The consortium formed by TURENNE GROUPE and GENEO Capital Entrepreneur has deployed the first €220 million tranche of Relance Bonds, and is now launching the new €117 million tranche.

GENEO Capital entrepreneur supports the Actéo group, which specializes in the manufacture (Théolaur) and distribution of paints and complementary products for the building industry (Théodore Maison de Peinture), in the evolution of its capital with a view to accelerating its development projects, notably around innovation, its low-carbon approach and digital. This transaction is part of a long-term, positive-impact investment strategy.

After 4 years marked by accelerated organic and external growth, HOPPEN has established itself as the French leader in phygital support for patients and healthcare establishments, reducing the workload of caregivers.

A benchmark player in its market and recently nominated for the French Tech 2030 award, the company is taking a new step forward with the acquisition of a stake in Après-demain SA, the parent company of Debiopharm™, a life sciences company, to accelerate its growth plan in Europe and consolidate its market leadership in digital solutions for patients before, during and after hospitalization.

Founded in 2019 by Fanny Letier and François Rivolier, GENEO Capital Entrepreneur currently manages over €600 million through three investment vehicles offering French companies, European leaders in their field, a wide range of financial products to support their growth over the long term.

Founded in 2019 by Fanny Letier and François Rivolier, GENEO Capital Entrepreneur currently manages over €600 million through three investment vehicles offering French companies, European leaders in their field, a wide range of financial products to support their growth over the long term.

Created in 1989, the Scutum Group has become one of the leaders in safety and security in Europe, providing technological solutions for protection and risk prevention, particularly through turnkey services for security, remote surveillance and fire detection.

Created in 1989, the Scutum Group has become one of the leaders in safety and security in Europe, providing technological solutions for protection and risk prevention, particularly through turnkey services for security, remote surveillance and fire detection.